In a multicentre Phase II study, the research team investigated the efficacy of zoliflodacin in the treatment of uncomplicated gonorrhea. The study period was from November 2014 to December 2015. The US study involved 179 subjects, including 167 men and 12 non-pregnant women between the ages of 18 and 55 years. Participants showed symptoms of uncomplicated genitourinary gonorrhea and had sexual contact with an infected individual within the last 14 days. Patients were randomized randomly at a ratio of 70:70:40 and either oral zoliflodacin at 2 g and 3 g as a single or a single dose intramuscular injection with 500 mg ceftriaxone treated as a comparator. After six days, the first check-up took place and another after 31 days. The primary measure of effectiveness was microbiological healing in the urogenital area. After six days, 96 percent (55 out of 57) of the subjects treated with 2 g zoliflodacin were treated with urogenital gonorrhea, 96 percent (54 out of 56) under 3 g zoliflodacin and 100 percent (28 out of 28) on ceftriaxone. The 15 subjects with rectal gonorrhea 100% of all study arms were healed. Compared to ceftriaxone, the new antibiotic was inferior to the treatment of gonorrhea infections of the pharynx. Four out of eight subjects treated with 2 g zoliflodacin were considered cured. There were 9 out of 11 participants among 3 g and all four subjects in the comparison group with ceftriaxone.